News

Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus. ( Picture: © Nico Michaelsen, Evotec SE)

24.05.2023 Senator Dr. Melanie Leonhard visits Evotec

Evotec SE announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating ...

For academic research, MHH will receive access to the data generated within the partnership by working with Evotec’s AI-driven analytics software PanHunter. (Picture: © Evotec)

25.10.2022 Evotec enters partnership with Hannover Medical School

Evotec SE announced that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to ...

Preview of the new biologics manufacturing plant J.POD® Toulouse, France (EU); (Image: © Brunerie & Irissou Architectes, Thomas Brunerie)

16.09.2022 Evotec initiates ground-breaking for new biologics facility

Evotec SE today officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, ...

Aurobac will work to shift the strategy related to antibiotic treatment regimens, which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. (Picture: © stock.adobe.com/Christoph Burgstedt)

06.07.2022 Evotec, Boehringer Ingelheim and bioMérieux cooperate

Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a ...

04.03.2022 Evotec: strategic roadmap towards precision medicine

Evotec SE presents at its virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning (“ML”) enabled precision technologies in discovery ...

The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2. (Picture: ©NicoElNino/adobe.stock.com)

04.01.2022 Evotec: € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...

Evotec is excited to provide a new compound that has the potential to improve the lives of many women

17.12.2021 Evotec receives US$ 18 m grant for women's health

Evotec SE announced that the Company has received a US$ 18 m grant from the Bill & ...

01.11.2021 Evotec Initiates US IPO

Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance ...

18.10.2021 Evotec: Collaboration with Bristol Myers Squibb

Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 ...

The facility employs J.POD® technology that uses autonomous clean rooms to run small, highly intensified production processes, thereby reducing the cost of biologics manufacturing. (Picture: ©Benjamin Benschneider)

12.08.2021 Just - Evotec Biologics opens J.POD® 1 US

Evotec SE announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. ...

Evotec creates further opportunities for long-term growth with "Campus Levi-Montalcini" in Verona. (Picture: ©Z S / Unsplash)

05.07.2021 Evotec creates long-term growth opportunities

Evotec SE announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA (“GSK”). ...

11.05.2021 Evotec SE reports results for the first quarter 2021

Evotec SE today announced the financial results and corporate updates for the first quarter 2021. ...

1
2

News

Manager PR & Communications Jan Phillip Denkers